(ANSA) - ROME, JUN 16 - On the second heterologous vaccination doses "we must be more than calm". DG Aifa, Nicola Magrini, told Rainews24. "In the decisions taken in this phase of the pandemic, less heavy than a few weeks ago, the choice was made - he explained - to avoid that in this phase young populations are potentially offered vaccines that have a very remote risk of a severe event, and therefore safety is was privileged to ensure that vaccines are maximally safe for all ". It is a "choice also shared by several countries, so I believe that trust and maximum tranquility is the message to be given".
At the basis of the heterolog vaccination, he concluded, "there are clinical trials that were carried out with the utmost ethical rigor, but they were not particularly problematic studies. The doubt was whether more unwanted effects and of what magnitude would be found, and are mostly mild or moderate effects. , and therefore the safety as regards the administration is very high ". (HANDLE).